A technology evaluation of the Onyx Frontier drug-eluting stent
INTRODUCTION: Onyx FrontierTM represents the latest iteration within the family of zotarolimus-eluting stents (ZES), designed for the treatment of coronary artery disease. Approval by the Food and Drug Administration was granted in May 2022, and Conformité Européenne marking followed in August 2022.
AREAS COVERED: We hereby review the principal design features of Onyx Frontier, highlighting differences and similarities with other currently available drug-eluting stents. In addition, we focus on the refinements of this newest platform as compared with previous ZES versions, including the attributes yielding its exceptional crossing profile and deliverability. The clinical implications related to both its newest and inherited characteristics will be discussed.
EXPERT OPINION: The nuances of the latest Onyx Frontier, together with the continuous refinement previously witnessed throughout the development of ZES, lead to a latest generation device ideal for a diverse spectrum of clinical and anatomical scenarios. In particular, its peculiarities will be of benefit in the settings often offered by a progressively aging population, such as high bleeding risk patients and complex coronary lesions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Expert opinion on drug delivery - 20(2023), 5 vom: 23. Mai, Seite 689-701 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Leone, Pier Pasquale [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cardiovascular Agents |
|---|
| Anmerkungen: |
Date Completed 19.06.2023 Date Revised 22.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/17425247.2023.2216449 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357057325 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357057325 | ||
| 003 | DE-627 | ||
| 005 | 20240123231840.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/17425247.2023.2216449 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1268.xml |
| 035 | |a (DE-627)NLM357057325 | ||
| 035 | |a (NLM)37203200 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Leone, Pier Pasquale |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A technology evaluation of the Onyx Frontier drug-eluting stent |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.06.2023 | ||
| 500 | |a Date Revised 22.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Onyx FrontierTM represents the latest iteration within the family of zotarolimus-eluting stents (ZES), designed for the treatment of coronary artery disease. Approval by the Food and Drug Administration was granted in May 2022, and Conformité Européenne marking followed in August 2022 | ||
| 520 | |a AREAS COVERED: We hereby review the principal design features of Onyx Frontier, highlighting differences and similarities with other currently available drug-eluting stents. In addition, we focus on the refinements of this newest platform as compared with previous ZES versions, including the attributes yielding its exceptional crossing profile and deliverability. The clinical implications related to both its newest and inherited characteristics will be discussed | ||
| 520 | |a EXPERT OPINION: The nuances of the latest Onyx Frontier, together with the continuous refinement previously witnessed throughout the development of ZES, lead to a latest generation device ideal for a diverse spectrum of clinical and anatomical scenarios. In particular, its peculiarities will be of benefit in the settings often offered by a progressively aging population, such as high bleeding risk patients and complex coronary lesions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Coronary artery disease | |
| 650 | 4 | |a Onyx frontier | |
| 650 | 4 | |a drug-eluting stent | |
| 650 | 4 | |a percutaneous coronary intervention | |
| 650 | 4 | |a zotarolimus | |
| 650 | 7 | |a zotarolimus |2 NLM | |
| 650 | 7 | |a H4GXR80IZE |2 NLM | |
| 650 | 7 | |a Cardiovascular Agents |2 NLM | |
| 700 | 1 | |a Assafin, Manaf |e verfasserin |4 aut | |
| 700 | 1 | |a Scotti, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Gonzalez, Maday |e verfasserin |4 aut | |
| 700 | 1 | |a Mignatti, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Dawson, Kathryn |e verfasserin |4 aut | |
| 700 | 1 | |a Rauch, Judah |e verfasserin |4 aut | |
| 700 | 1 | |a Khaliq, Asma |e verfasserin |4 aut | |
| 700 | 1 | |a Bliagos, Dimitrios |e verfasserin |4 aut | |
| 700 | 1 | |a Latib, Azeem |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on drug delivery |d 2004 |g 20(2023), 5 vom: 23. Mai, Seite 689-701 |w (DE-627)NLM159019028 |x 1744-7593 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2023 |g number:5 |g day:23 |g month:05 |g pages:689-701 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/17425247.2023.2216449 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2023 |e 5 |b 23 |c 05 |h 689-701 | ||